Rupa Patel1, Stephen Charles1, Assad Jalil2,3. 1. Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre and Institute of Human Development, University of Manchester, Manchester, UK. 2. Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre and Institute of Human Development, University of Manchester, Manchester, UK. assadjalil@hotmail.com. 3. Vitreoretinal Surgeon and Uveitis Specialist, Manchester Royal Eye Hospital, Oxford Road, Manchester, M13 9WH, UK. assadjalil@hotmail.com.
Abstract
PURPOSE: To survey current practice and opinion regarding the cessation of antiplatelet and anticoagulant agents prior to vitreoretinal surgery, with special emphasis on novel anticoagulants, and to provide an overview of current literature. METHODS: An online survey was sent to 167 members of the British and Eire Association of Vitreoretinal Surgeons (BEAVRS). A literature search and analysis was conducted on studies that reviewed the bleeding risk of antiplatelet and anticoagulant agents. RESULTS: The majority (93% for aspirin, 82% for clopidogrel) of respondents would not suspend antiplatelet administration, and 79% would not stop warfarin before vitreoretinal surgery. Regarding the novel anticoagulants (factor Xa inhibitors), 58% would not stop them, and 24% were unsure. Eighty-three percent of the surgeons were not confident regarding the management of factor Xa inhibitors preoperatively. Thirty-one percent of the respondents felt that anticoagulation cessation was independent of the type of vitreoretinal surgery, whereas 9% each felt that they would stop anticoagulation if possible for diabetic vitrectomy and retinectomy. Published evidence suggests that antiplatelet agents and warfarin do not confer a significantly greater risk of intra- or perioperative bleeding. Evidence regarding the novel anticoagulants is sparse. CONCLUSIONS: Further evaluation of novel anticoagulants in vitreoretinal surgery is required in order to provide evidence-based recommendations and address variations in practice.
PURPOSE: To survey current practice and opinion regarding the cessation of antiplatelet and anticoagulant agents prior to vitreoretinal surgery, with special emphasis on novel anticoagulants, and to provide an overview of current literature. METHODS: An online survey was sent to 167 members of the British and Eire Association of Vitreoretinal Surgeons (BEAVRS). A literature search and analysis was conducted on studies that reviewed the bleeding risk of antiplatelet and anticoagulant agents. RESULTS: The majority (93% for aspirin, 82% for clopidogrel) of respondents would not suspend antiplatelet administration, and 79% would not stop warfarin before vitreoretinal surgery. Regarding the novel anticoagulants (factor Xa inhibitors), 58% would not stop them, and 24% were unsure. Eighty-three percent of the surgeons were not confident regarding the management of factor Xa inhibitors preoperatively. Thirty-one percent of the respondents felt that anticoagulation cessation was independent of the type of vitreoretinal surgery, whereas 9% each felt that they would stop anticoagulation if possible for diabetic vitrectomy and retinectomy. Published evidence suggests that antiplatelet agents and warfarin do not confer a significantly greater risk of intra- or perioperative bleeding. Evidence regarding the novel anticoagulants is sparse. CONCLUSIONS: Further evaluation of novel anticoagulants in vitreoretinal surgery is required in order to provide evidence-based recommendations and address variations in practice.
Entities:
Keywords:
Anticoagulants; Antiplatelets; Bleeding; Factor Xa inhibitors; Novel anticoagulants; Vitreoretinal surgery
Authors: Kim A Eagle; Robert A Guyton; Ravin Davidoff; Fred H Edwards; Gordon A Ewy; Timothy J Gardner; James C Hart; Howard C Herrmann; L David Hillis; Adolph M Hutter; Bruce Whitney Lytle; Robert A Marlow; William C Nugent; Thomas A Orszulak Journal: Circulation Date: 2004-10-05 Impact factor: 29.690
Authors: Clive Kearon; Susan R Kahn; Giancarlo Agnelli; Samuel Goldhaber; Gary E Raskob; Anthony J Comerota Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Arthur D Fu; H Richard McDonald; David F Williams; Herbert L Cantrill; Edwin H Ryan; Robert N Johnson; Everett Ai; J Michael Jumper Journal: Retina Date: 2007-03 Impact factor: 4.256
Authors: J D Benzimra; R L Johnston; P Jaycock; P H Galloway; G Lambert; A K K Chung; T Eke; J M Sparrow Journal: Eye (Lond) Date: 2008-02-08 Impact factor: 3.775
Authors: N Feltgen; B Mele; T Dietlein; C Erb; A Eckstein; A Hager; A Heiligenhaus; H Helbig; H Hoerauf; E Hoffmann; D Pauleikhoff; M Schittkowski; B Seitz; C Sucker; S Suffo; U Schaudig; F Tost; S Thurau; P Walter; J Koscielny Journal: Ophthalmologe Date: 2018-07 Impact factor: 1.059
Authors: Sebastian Bemme; Peer Lauermann; Nina Antonia Striebe; Mohammed Haitham Khattab; Johannes Affeldt; Josep Callizo; Thomas Bertelmann; Sebastian Pfeiffer; Hans Hoerauf; Nicolas Feltgen Journal: Graefes Arch Clin Exp Ophthalmol Date: 2020-01-07 Impact factor: 3.117
Authors: Oliver Zeitz; Laura Wernecke; Nicolas Feltgen; Christoph Sucker; Jürgen Koscielny; Thomas Dörner Journal: Ophthalmologe Date: 2021-07-19 Impact factor: 1.059